UC San Diego Health Supports Pride in Parade
|
Our Community Outreach and Equity (COE) team proudly represented Moores Cancer Center at this year's San Diego Pride Parade, celebrating diversity and inclusion within our community.
Associate Director of Population Science, Dr. Elena Martinez and Associate Director of Community Outreach and Engagement, Dr. Jesse Nodora were in attendance. Our outreach team connected with over 300 visitors, showcasing our commitment to a world where everyone feels seen, heard, and valued.
Thank you to everyone who joined UC San Diego Health and supported this meaningful event.
|
|
|
Usha Mahajani Symposium on Molecular Medicine: Physical Forces and the Hallmarks of Cancer
|
Moores will co-host the 35th Annual Usha Mahajani Symposium, organized by Moores Member Jing Yang, PhD. This symposium will enable graduate students and postdoctoral fellows to engage with esteemed international experts in the specialized area of biomedical research related to cancer.
|
Moores Member Published in ASCO Educational Book
|
Rebecca Shatsky, MD, from MCC, collaborated on “Systemic Therapy in Breast Cancer,” which was recently published in ASCO’s Educational Book. Learn more below as Dr. Shatsky dives into how therapeutic advances in breast cancer have significantly improved outcomes in recent decades.
|
Moores Hosts COSMOS Summer Program Tour
|
COSMOS, a summer high school program run out of the Jacobs School of Engineering, toured MCC on July 15, 2024, with the goal of seeing how computers and medicine intertwine in our research labs. The students toured Gutkind, Biorepository, and BRACHY labs and had a panel discussion with Alejandro Campos, PhD; Asimini Courelli, MD; JungHo Kong, PhD; Mark Antkowiak, MD; and Matt Heard, MD.
|
RMAS Grand Rounds: Cervical Cancer Innovation through Clinical Trial Development and Global Training
|
Radiation Medicine and Applied Sciences (RMAS) Grand Rounds is an opportunity for leading experts in the field to expand their knowledge, engage in interdisciplinary discussions, and stay abreast of advancements in radiation therapy. Moores will host its first of the year on September 16, 2024, as Jyoti Mayadev, MD, discusses cervical cancer innovation through clinical trial development and global training.
|
|
|
August 7, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
August 9, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
August 21, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
September 19, 2024 | 8:30 a.m. to 6:30 p.m.
Duane Roth Auditorium (Sanford Consortium for Regenerative Medicine)
|
Testicular Cancer Awareness Foundation
|
Timothy A. Masterson, MD and T. Clark Gamblin, MD, MS, MBA
|
September 19–21, 2024
Moores Goldberg Auditorium
|
|
|
FEATURED FUNDING OPPORTUNITIES |
Breast Cancer Research Program (BCRP) Breakthrough Award Levels 1 and 2
|
The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation, stimulate creativity, and facilitate productive collaborations.
The Breakthrough Award has four different funding levels. The current program announcement discusses Breakthrough Award Levels 1 and 2. Before submitting the pre-application, the PI is strongly encouraged to review the research scope defined under each funding level as described in the corresponding Breakthrough Award program announcement.
LOI Deadline - September 12, 2024
Application Deadline - September 26, 2024
Budget | Period: $450,000 - 2,000,000 (varies) | 3-4 years
|
|
|
| Cockayne Syndrome Linked to Elevated R-Loops Induced by Stalled RNA Polymerase II during Transcription Elongation
|
Dong Wang PhD (Cancer Biology and Signaling)
|
|
|
|
Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer
|
Prostate Cancer and Prostatic Diseases
|
Rana R. McKay MD (Solid Tumor Therapeutics)
|
|
|
| A kinome-wide synthetic lethal CRISPR/Cas9 screen reveals that mTOR inhibition prevents adaptive resistance to CDK4/CDK6 blockade in HNSCC
|
Cancer Research Communications
|
Prashant Mali PhD (Cancer Biology and Signaling), J. Silvio Gutkind PhD (Cancer Biology and Signaling)
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
MYTX-011-01: A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX011 in Subjects With Non-Small Cell Lung Cancer KisMET01
|
PI: Lyudmila Bazhenova, MD
NCT: NCT05652868
|
|
|
|
